Open AccessCombining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections
Author(s) -
S.L. Durfey,
Sudhakar Pipavath,
Anna Li,
Anh T. Vo,
Anina Ratjen,
Suzanne Carter,
Sarah J. Morgan,
Matthew C. Radey,
Brenda Grogan,
Stephen J. Salipante,
Michael J. Welsh,
David A. Stoltz,
Christopher H. Goss,
Edward F. McKone,
Pradeep K. Singh
Publication year - 2021
Publication title -
mbio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.562
H-Index - 121
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.03148-21
Subject(s) - ivacaftor , cystic fibrosis , pseudomonas aeruginosa , antibiotics , medicine , staphylococcus aureus , pathogen , lung , inflammation , bronchiectasis , immunology , microbiology and biotechnology , biology , cystic fibrosis transmembrane conductance regulator , bacteria , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom